TARX (Tarsier Pharma) Book Value per Share: $-0.17 (As of Dec. 2025)


What is Tarsier Pharma Book Value per Share?

Tarsier Pharma TARX Book Value per Share is $-0.17 as of Dec. 2025.

Tarsier Pharma's book value per share for the quarter that ended in Dec. 2025 was $-0.17.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

Tarsier Pharma's current price is $0.00. Its book value per share for the quarter that ended in Dec. 2025 was $-0.17. Hence, today's PB Ratio of Tarsier Pharma is .

Tarsier Pharma  (NYSE:TARX) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

Tarsier Pharma Book Value per Share Related Terms

Tarsier Pharma Book Value per Share Historical Data

* Premium members only.

The historical data trend for Tarsier Pharma's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsier Pharma Book Value per Share Chart

Tarsier Pharma Annual Data
Trend Dec23 Dec24 Dec25
Book Value per Share
-0.08 -0.10 -0.17

Tarsier Pharma Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Book Value per Share -0.08 0.00 -0.10 -0.10 -0.17

TARX vs : Book Value per Share Comparison

For the Biotechnology subindustry, Tarsier Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tarsier Pharma PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tarsier Pharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Tarsier Pharma's PB Ratio falls into.


Tarsier Pharma Book Value per Share Calculation

Tarsier Pharma's Book Value Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-4.99-0.00)/28.74
=-0.17

Tarsier Pharma's Book Value Per Share for the quarter that ended in Dec. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-4.99-0.00)/28.74
=-0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →
What does a Book Value per Share of $-0.17 mean?
Tarsier Pharma (TARX) has a Book Value per Share of $-0.17 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Tarsier Pharma and its competitors.
Is Tarsier Pharma's Book Value per Share too high?
Tarsier Pharma's current Book Value per Share is $-0.17.
How does Tarsier Pharma's Book Value per Share compare to ?
Tarsier Pharma's Book Value per Share of $-0.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Tarsier Pharma and its competitors. Tarsier Pharma's current Book Value per Share is $-0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsier Pharma stock overvalued right now?
Tarsier Pharma (TARX) has a current Book Value per Share of $-0.17. The current Book Value per Share is $-0.17. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Tarsier Pharma (TARX), the current Book Value per Share is $-0.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tarsier Pharma Business Description

Comparable Companies
Tarsier Pharma Ltd is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet needs in ocular diseases with underlying inflammatory pathologies. Its dazdotuftide platform technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops and intravitreal injections. The company's Product Candidate Pipeline includes TRS01 and TRS02.